Author: Lynch Regenerative Medicine, LLC

FDA Authorizes Lynch Regenerative Medicine’s IND for a Phase IIb Clinical Trial for Injection of rhPDGF-BB for Treatment of Infraorbital Hollowing

October 21, 2026
Lynch Regenerative Medicine Announces Completion of Enrollment in a Phase II Clinical Trial Evaluating rhPDGF-BB in the Reconstruction of Full-Thickness Head or Neck Defects Following Skin Cancer Excision

August 18, 2026

FDA Authorizes Lynch Regenerative Medicine’s IND for a Phase IIb Clinical Trial for Injection of rhPDGF-BB for Treatment of Infraorbital Hollowing